Skip to main content
SpringerLink
Log in

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor (HR) positive (HR+) status and, nowadays, are used in the adjuvant and neoadjuvant settings, and first-line therapy for advanced breast cancer. Letrozole is a third generation AI, as are anastrozole and exemestane. In the past, clinical studies had demonstrated that letrozole was effective as a second-line treatment of metastatic breast cancer. In this paper, pharmacokinetic and pharmacodynamic properties of letrozole are reviewed along with its activity in preclinical and clinical settings. Additionally, the results of important clinical trials such as Breast International Group (BIG) 1-98, which tested the optimal initial adjuvant endocrine treatment and the sequential therapy with letrozole and tamoxifen, MA-17 that evaluates the benefits of extended adjuvant therapy, and other important studies in advanced and neoadjuvant disease, are reviewed. Safety comparisons of treatments are also addressed. Interestingly, about 50% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers are HR+. However, HER2 positivity is a marker of antiestrogen treatment resistance. Because of this, a dual treatment is a logical approach when both receptors are overexpressed. The combination of lapatinib and letrozole leads to a significant improvement in the overall disease outcome. Also, the combination of everolimus plus letrozole has been tested in this setting. In fact, the coadministration of both agents seems to increase the efficacy of letrozole in newly-diagnosed HR+ patients. Once resistance to sequential trastuzumab and AI as monotherapy has been found, trastuzumab and letrozole combined in HR+ and HER2+ patients with advanced breast cancer can overcome resistance to both drugs administered as single agents, according to recently reported results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheung AM, Chaudhry R, Kapral M, Jackevicius C, Robinson G. Perimenopausal and Postmenopausal Health. BMC Womens Health. 2004;4(Suppl. 1):S23.

    Article  PubMed  Google Scholar 

  2. Vogel VG. Breast cancer prevention: a review of current evidence. CA Cancer J Clin. 2000;50:156–170.

    Article  PubMed  CAS  Google Scholar 

  3. NHS Breast Screening Programme and Association of Breast Surgery at BASO. Audit of screen detected breast cancers for the year of screening April 2004 to March 2005. Available at: http://www.cancerscreening.nhs.uk/breastscreen/publications/baso2004-2005.pdf. Last accessed May 5, 2011.

  4. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007 Jul; 1(26): iii–iv, ix–xi, 1–134. Availabe at: http://www.hta.nhs.uk/pdfexecs/summ1126.pdf. Last accessed May 5, 2011.

    Google Scholar 

  5. Stanley A. Breast cancer. Treatment of early disease. Hospital Pharmacist. 2004;11:415–420.

    Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467.

    Article  Google Scholar 

  7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.

  8. Kilian R, Porzsolt F. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature. Breast. 2005;14:636–642.

    Article  PubMed  Google Scholar 

  9. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62.

    Article  PubMed  CAS  Google Scholar 

  10. Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005;11:2809–2821.

    Article  PubMed  CAS  Google Scholar 

  11. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009:CD003370.

  12. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev. 2008;34:157–174.

    Article  PubMed  CAS  Google Scholar 

  13. Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer. 2004;101:1482–1489.

    Article  PubMed  CAS  Google Scholar 

  14. Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999;5:2338–2343.

    PubMed  CAS  Google Scholar 

  15. Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos. 2001;22:191–197.

    Article  PubMed  CAS  Google Scholar 

  16. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003;30(Suppl. 14):23–32.

    Article  PubMed  CAS  Google Scholar 

  17. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003;87:35–45.

    Article  PubMed  CAS  Google Scholar 

  18. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007;105(Suppl. 1):7–17.

    Article  PubMed  CAS  Google Scholar 

  19. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol. 2006;102:97–102.

    Article  PubMed  CAS  Google Scholar 

  20. Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem Mol Biol. 2007;106:119–124.

    Article  PubMed  CAS  Google Scholar 

  21. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 1999;57:183–192.

    Article  PubMed  CAS  Google Scholar 

  22. Mokbel K. The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol. 2002;7:279–283.

    PubMed  CAS  Google Scholar 

  23. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003;63:6523–6531.

    PubMed  CAS  Google Scholar 

  24. Murray J, Young OE, Renshaw L, et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat. 2009;114:495–501.

    Article  PubMed  CAS  Google Scholar 

  25. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1995;1:1511–1515.

    PubMed  CAS  Google Scholar 

  26. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751–757.

    Article  PubMed  CAS  Google Scholar 

  27. Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14:6330–6335.

    Article  PubMed  CAS  Google Scholar 

  28. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer. 1999;6:187–195.

    Article  PubMed  CAS  Google Scholar 

  29. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 2001;79:93–102.

    Article  PubMed  CAS  Google Scholar 

  30. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol. 2001;79:103–107.

    Article  PubMed  CAS  Google Scholar 

  31. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999;35:208–213.

    Article  PubMed  CAS  Google Scholar 

  32. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 1993;53:266–270.

    PubMed  CAS  Google Scholar 

  33. Klein KO, Demers LM, Santner SJ, Baron J, Cutler GB, Jr., Santen RJ. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab. 1995;80:2658–2660.

    Article  PubMed  CAS  Google Scholar 

  34. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 1995;75:2132–2138.

    Article  PubMed  CAS  Google Scholar 

  35. Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27:3192–3197.

    Article  PubMed  CAS  Google Scholar 

  36. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671–1676.

    Article  PubMed  CAS  Google Scholar 

  37. Goss PE. Letrozole in the extended adjuvant setting: MA-17. Breast Cancer Res Treat. 2007;105(Suppl. 1):45–53.

    Article  PubMed  CAS  Google Scholar 

  38. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757.

    Article  PubMed  Google Scholar 

  39. Brodie AH, Mouridsen HT. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. Am J Clin Oncol. 2003;26:S17–26.

    Article  PubMed  Google Scholar 

  40. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005;65:5439–5444.

    Article  PubMed  CAS  Google Scholar 

  41. Bajetta E, Celio L, Buzzoni R, Bichisao E. Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Tumori. 1996;82:417–22.

    PubMed  CAS  Google Scholar 

  42. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. 2003;9(1 Pt 2):468S–472S.

    PubMed  CAS  Google Scholar 

  43. Nabholtz JM, Mouret-Reynier MA, Durando X, et al. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother. 2009;10:1435–1447.

    Article  PubMed  CAS  Google Scholar 

  44. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer. 2001;37:1510–1513.

    Article  PubMed  CAS  Google Scholar 

  45. Engan T, Krane J, Johannessen DC, Lonning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy—lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat. 1995;36:287–297.

    Article  PubMed  CAS  Google Scholar 

  46. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 2002;11:614–621.

    PubMed  CAS  Google Scholar 

  47. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA-17. J Clin Oncol. 2007;25:2006–2011.

    Article  PubMed  CAS  Google Scholar 

  48. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA-17. J Clin Oncol. 2006;24:3629–3635.

    Article  PubMed  CAS  Google Scholar 

  49. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA-17L). Ann Oncol. 2005;16:707–715.

    Article  PubMed  CAS  Google Scholar 

  50. Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001;79:109–114.

    Article  PubMed  CAS  Google Scholar 

  51. Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66:191–199.

    Article  PubMed  CAS  Google Scholar 

  52. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532.

    Article  PubMed  CAS  Google Scholar 

  53. Ingle JN, Johnson PA, Suman VJ, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 1997;80:218–224.

    Article  PubMed  CAS  Google Scholar 

  54. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492.

    Article  PubMed  CAS  Google Scholar 

  55. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776.

    Article  PubMed  CAS  Google Scholar 

  56. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–2109.

    Article  PubMed  CAS  Google Scholar 

  57. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–2606.

    PubMed  CAS  Google Scholar 

  58. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816.

    PubMed  CAS  Google Scholar 

  59. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 2008;68:4518–4524.

    Article  PubMed  CAS  Google Scholar 

  60. Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2 2010;15:122–129.

    Google Scholar 

  61. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.

    Article  PubMed  CAS  Google Scholar 

  62. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684.

    Article  PubMed  CAS  Google Scholar 

  63. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  64. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123:541–546.

    Article  PubMed  CAS  Google Scholar 

  65. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9:23–28.

    Article  PubMed  CAS  Google Scholar 

  66. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14:4484–4490.

    Article  PubMed  CAS  Google Scholar 

  67. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone-receptor metastasic breast cancer. J Clin Oncol. 2009;27:5538–5546.

    Article  PubMed  CAS  Google Scholar 

  68. Schwartzberg LS, Franco S, Florane A, et al. Lapatinib plus letrozole as first-line therapy for HER-2 positive hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15:122–129.

    Article  PubMed  Google Scholar 

  69. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630–2637.

    Article  PubMed  CAS  Google Scholar 

  70. Koeberle D, Ruhstaller T, Jost L, et al. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer. 2011;18:257–64.

    Article  PubMed  CAS  Google Scholar 

  71. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009;27:1382–1387.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Agustí Barnadas

  2. Medical Oncology Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

    Laura G. Estévez

  3. Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain

    Ana Lluch-Hernández

  4. Medical Oncology Department, Hospital General de Elche, Alicante, Spain

    Álvaro Rodriguez-Lescure

  5. Medical Oncology Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain

    César Rodriguez-Sanchez

  6. Medical Oncology Department, Hospital de Jaen, Jaen, Spain

    Pedro Sanchez-Rovira

Authors
  1. Agustí Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura G. Estévez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Lluch-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Álvaro Rodriguez-Lescure
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. César Rodriguez-Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pedro Sanchez-Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agustí Barnadas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barnadas, A., Estévez, L.G., Lluch-Hernández, A. et al. An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. Adv Therapy 28, 1045–1058 (2011). https://doi.org/10.1007/s12325-011-0075-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0075-4

Keywords

Search

Navigation